MitoCareX Bio Study Finds SLC25A as Biomarkers for Spaceflight
N2OFF highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for dysfunctions induced by spaceflight conditions, including microgravity and cosmic radiation. The study, titled "SLC25A mitochondrial carriers as biomarkers and therapeutic targets of spaceflight-induced dysfunction: the ADP/ATP carrier as a structural case study," was published online on December 30. The work integrates transcriptomic data from NASA's Open Science Data Repository, examining the expression of 53 SLC25A genes in osteocytes, human bone marrow-derived mesenchymal stem cells, and mouse brain tissue exposed to microgravity and spaceflight-related stressors. The analysis identified differential regulation of multiple SLC25A carriers under spaceflight conditions, supporting their potential utility as biomarkers of mitochondrial and metabolic dysfunction. The ADP/ATP carrier AAC3 was further examined as a structural case study, based on comparative modeling and structure-function analyses to illustrate how carrier conformational features may be targeted to rescue mitochondrial bioenergetics under stress. While this independent academic research- conducted in collaboration with the University of Bari "Aldo Moro" and the University of Pittsburgh-was not performed under MitoCareX Bio's auspices, it directly aligns with the Company's core scientific area of focus on mitochondrial carrier biology. MitoCareX Bio applies proprietary approaches, including the MITOLINE algorithm to virtually model, screen and validate small-molecule modulators targeting the SLC25A family of mitochondrial carriers. These proteins, central to cellular energy metabolism, play central roles in hard-to-treat indications including in several types of cancer, metabolic diseases related to the metabolic syndrome, and are also implicated in rare inherited disorders associated with neuromuscular degeneration, which share mechanistic similarities with physiological alterations observed in astronauts.
Trade with 70% Backtested Accuracy
Analyst Views on NITO
About NITO
About the author
N2OFF Highlights New Study on SLC25A Biomarkers and Therapeutic Targets
- Research Publication: N2OFF's wholly-owned subsidiary MitoCareX Bio co-authored a study with the University of Bari and the University of Pittsburgh, highlighting SLC25A mitochondrial carriers as potential biomarkers for spaceflight-induced dysfunction, emphasizing their significance in tumor metabolic adaptation and therapy resistance.
- Data Integration Analysis: The study integrates transcriptomic data from NASA's Open Science Data Repository, examining the expression of 53 SLC25A genes under microgravity and spaceflight-related stressors, revealing differential regulation of multiple carriers that supports their potential as biomarkers of mitochondrial and metabolic dysfunction.
- Structural Case Study: The research specifically investigates the ADP/ATP carrier AAC3, using comparative modeling and structure-function analyses to illustrate how targeting carrier conformational features can rescue mitochondrial bioenergetics under stress, further advancing precision oncology research.
- Investment Strategy Alignment: N2OFF is not only focused on drug discovery but also invests in European renewable energy assets using the RTB business model, currently serving as the lead investor in four solar projects across three EU countries, demonstrating its strategic positioning in sustainable development.
N2OFF Partners with Solterra to Advance German Solar Project
- Significant Project Progress: N2OFF's partnership with Solterra has achieved key milestones in reducing permitting risks for its German solar project, which is on track for approval in Q3 2026, indicating strong positioning in the European market.
- Financial Optimization: By advancing $340,000, Solterra secured more favorable profit-sharing terms, expected to create approximately $1.7 million in project value, enhancing the company's financial flexibility and profitability.
- Strategic Investment: This transaction represents a highly efficient redeployment of limited near-term capital, not only improving long-term project economics but also enhancing future exit or operating return potential, showcasing N2OFF's discipline in capital allocation.
- Optimistic Market Outlook: With systematic reductions in regulatory risks and tightening development economics, N2OFF's advancement along the RTB value curve will lay a solid foundation for the company's long-term growth in the renewable energy sector.
N2OFF Partners with Solterra to Advance European Solar Projects
- Reduced Permitting Risk: Strong progress in Germany's public consultation with zero objections and formal planning submissions in Italy enhance approval visibility, ensuring smooth project advancement.
- Over $1.69 Million in Value Creation: Strategic renegotiation in Germany optimizes returns through disciplined, capital-efficient moves, significantly improving the project's financial performance.
- High-Upside Monetization Flexibility: Italian battery storage projects are primed for value realization in H2 2026, offering options for sale or build-and-operate based on partner strategy.
- Germany Project on Track: The flagship project is on track for Q3 2026 approval, with savings exceeding $1.69 million, demonstrating strong regulatory and community support to ensure the project proceeds as planned.
N2OFF: MitoCareX Discovers Promising Compounds and Targets for Preclinical Candidate Selection
Company Acquisition and Strategic Direction: N2OFF, Inc. has acquired MitoCareX Bio Ltd., with CEO Dr. Alon Silberman outlining the company's focus on precision oncology and the development of novel therapies targeting aggressive cancers using their proprietary MITOLINE™ algorithm.
Innovative Drug Discovery Approach: MitoCareX is leveraging MITOLINE™ for drug discovery, aiming to create first-in-class therapeutics that disrupt cancer metabolism, particularly for lung and pancreatic cancers, which represent a significant market opportunity.
Short-Term and Long-Term Goals: The company plans to optimize hit compounds and prepare for preclinical development in 2026, while also exploring strategic collaborations to expand MITOLINE™'s applications and generate non-dilutive revenue.
Future Outlook and Mission: MitoCareX aims to establish itself as a leader in drug discovery by focusing on mitochondrial biology and precision oncology, with a mission to transform insights into value for patients and shareholders through a scalable discovery platform.
N2OFF Finalizes Merger with Cancer Drug Discovery Firm Focused on Challenging Pancreatic and Lung Cancers
Merger Announcement: N2OFF, Inc. has completed its merger with MitoCareX Bio Ltd, a biotech company focused on cancer therapeutics, enhancing N2OFF's portfolio in the cleantech and biotech sectors.
MitoCareX's Focus: MitoCareX is developing novel therapies targeting mitochondrial SLC25 proteins to treat hard-to-treat cancers, utilizing its proprietary MITOLINE™ algorithm for drug discovery.
Financial Details: N2OFF acquired MitoCareX for $700,000 and common stock representing 40% of N2OFF's fully diluted capital stock, with additional financial commitments to support MitoCareX's operations for two years.
Market Potential: The global cancer therapeutics market is projected to grow from $211.02 billion in 2025 to $378.62 billion by 2032, indicating significant opportunities for MitoCareX's innovations in cancer treatment.
SciSparc Shares Jump 50% in Pre-Market Following N2OFF's Approval of MitoCareX Acquisition
Acquisition Approval: SciSparc Ltd. shares surged over 58% after N2OFF Inc. stockholders approved the acquisition of SciSparc's subsidiary, MitoCareX Bio Ltd., which will become wholly owned by N2OFF.
Financial Terms of the Deal: N2OFF will purchase MitoCareX for $0.7 million and exchange shares with the sellers, who will also receive 30% of financing proceeds raised by N2OFF for five years, up to $1.6 million.
N2OFF Highlights New Study on SLC25A Biomarkers and Therapeutic Targets
- Research Publication: N2OFF's wholly-owned subsidiary MitoCareX Bio co-authored a study with the University of Bari and the University of Pittsburgh, highlighting SLC25A mitochondrial carriers as potential biomarkers for spaceflight-induced dysfunction, emphasizing their significance in tumor metabolic adaptation and therapy resistance.
- Data Integration Analysis: The study integrates transcriptomic data from NASA's Open Science Data Repository, examining the expression of 53 SLC25A genes under microgravity and spaceflight-related stressors, revealing differential regulation of multiple carriers that supports their potential as biomarkers of mitochondrial and metabolic dysfunction.
- Structural Case Study: The research specifically investigates the ADP/ATP carrier AAC3, using comparative modeling and structure-function analyses to illustrate how targeting carrier conformational features can rescue mitochondrial bioenergetics under stress, further advancing precision oncology research.
- Investment Strategy Alignment: N2OFF is not only focused on drug discovery but also invests in European renewable energy assets using the RTB business model, currently serving as the lead investor in four solar projects across three EU countries, demonstrating its strategic positioning in sustainable development.
N2OFF Partners with Solterra to Advance German Solar Project
- Significant Project Progress: N2OFF's partnership with Solterra has achieved key milestones in reducing permitting risks for its German solar project, which is on track for approval in Q3 2026, indicating strong positioning in the European market.
- Financial Optimization: By advancing $340,000, Solterra secured more favorable profit-sharing terms, expected to create approximately $1.7 million in project value, enhancing the company's financial flexibility and profitability.
- Strategic Investment: This transaction represents a highly efficient redeployment of limited near-term capital, not only improving long-term project economics but also enhancing future exit or operating return potential, showcasing N2OFF's discipline in capital allocation.
- Optimistic Market Outlook: With systematic reductions in regulatory risks and tightening development economics, N2OFF's advancement along the RTB value curve will lay a solid foundation for the company's long-term growth in the renewable energy sector.
N2OFF Partners with Solterra to Advance European Solar Projects
- Reduced Permitting Risk: Strong progress in Germany's public consultation with zero objections and formal planning submissions in Italy enhance approval visibility, ensuring smooth project advancement.
- Over $1.69 Million in Value Creation: Strategic renegotiation in Germany optimizes returns through disciplined, capital-efficient moves, significantly improving the project's financial performance.
- High-Upside Monetization Flexibility: Italian battery storage projects are primed for value realization in H2 2026, offering options for sale or build-and-operate based on partner strategy.
- Germany Project on Track: The flagship project is on track for Q3 2026 approval, with savings exceeding $1.69 million, demonstrating strong regulatory and community support to ensure the project proceeds as planned.
N2OFF: MitoCareX Discovers Promising Compounds and Targets for Preclinical Candidate Selection
Company Acquisition and Strategic Direction: N2OFF, Inc. has acquired MitoCareX Bio Ltd., with CEO Dr. Alon Silberman outlining the company's focus on precision oncology and the development of novel therapies targeting aggressive cancers using their proprietary MITOLINE™ algorithm.
Innovative Drug Discovery Approach: MitoCareX is leveraging MITOLINE™ for drug discovery, aiming to create first-in-class therapeutics that disrupt cancer metabolism, particularly for lung and pancreatic cancers, which represent a significant market opportunity.
Short-Term and Long-Term Goals: The company plans to optimize hit compounds and prepare for preclinical development in 2026, while also exploring strategic collaborations to expand MITOLINE™'s applications and generate non-dilutive revenue.
Future Outlook and Mission: MitoCareX aims to establish itself as a leader in drug discovery by focusing on mitochondrial biology and precision oncology, with a mission to transform insights into value for patients and shareholders through a scalable discovery platform.
N2OFF Finalizes Merger with Cancer Drug Discovery Firm Focused on Challenging Pancreatic and Lung Cancers
Merger Announcement: N2OFF, Inc. has completed its merger with MitoCareX Bio Ltd, a biotech company focused on cancer therapeutics, enhancing N2OFF's portfolio in the cleantech and biotech sectors.
MitoCareX's Focus: MitoCareX is developing novel therapies targeting mitochondrial SLC25 proteins to treat hard-to-treat cancers, utilizing its proprietary MITOLINE™ algorithm for drug discovery.
Financial Details: N2OFF acquired MitoCareX for $700,000 and common stock representing 40% of N2OFF's fully diluted capital stock, with additional financial commitments to support MitoCareX's operations for two years.
Market Potential: The global cancer therapeutics market is projected to grow from $211.02 billion in 2025 to $378.62 billion by 2032, indicating significant opportunities for MitoCareX's innovations in cancer treatment.
SciSparc Shares Jump 50% in Pre-Market Following N2OFF's Approval of MitoCareX Acquisition
Acquisition Approval: SciSparc Ltd. shares surged over 58% after N2OFF Inc. stockholders approved the acquisition of SciSparc's subsidiary, MitoCareX Bio Ltd., which will become wholly owned by N2OFF.
Financial Terms of the Deal: N2OFF will purchase MitoCareX for $0.7 million and exchange shares with the sellers, who will also receive 30% of financing proceeds raised by N2OFF for five years, up to $1.6 million.
